{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 84,
  "pageCount": 95,
  "prevPage": 83,
  "nextPage": 85,
  "slideType": "transition",
  "function": "transition",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Includes a disclaimer regarding the basis of estimates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/84",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-84",
  "components": [
    {
      "bbox": {
        "h": 0.033,
        "w": 0.389,
        "x": 0.056,
        "y": 0.933
      },
      "kind": "disclaimer",
      "text": "These estimates are based on public data, industry trends, and experience. The Board will review and revise as needed should our slate be elected.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff366152-73d0-47c2-820b-a0eea3914643",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.156,
        "w": 0.118,
        "x": 0.441,
        "y": 0.667
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3101de9d-4685-432e-9971-0fa4fffb2a14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.558,
        "x": 0.221,
        "y": 0.263
      },
      "kind": "paragraph",
      "text": "We expect to incur approximately $1.7M in costs associated with transitioning personnel including severance and bringing in career transition services.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b903fb51-c946-47aa-a214-7ea7cc4bb2d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.558,
        "x": 0.221,
        "y": 0.461
      },
      "kind": "paragraph",
      "text": "We expect to incur an additional $1M in costs associated with the MM-120 Phase IIb program in Q4 2023 which are reflected in the “Other Programs” line item.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da171c2a-0676-4bad-b887-982733c58b59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.397,
        "x": 0.047,
        "y": 0.056
      },
      "kind": "title",
      "text": "Transition Cost",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5488b5b-8a39-4896-90ea-57244626ca4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 95,
      "from": 61,
      "beatId": "383f2f65-7b68-449f-b311-9bc0591c8aab",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Freeman Capital Management's plan to restore value in Mind Medicine, including bringing MM-120 to market quickly and safely, and aligning G&A and headcount.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}